ESG

Astellas Pharma's new deal with venture studio Autobahn Labs isn't just a partnership; it's a strategic overhaul of the R&D pipeline. Here's why.

Roivant Sciences reveals accelerated timelines for key drugs and a bold three-year growth plan, pivoting its unique 'Vant' model toward commercialization.

Biomerica's regulatory win in Egypt is more than a market entry; it's a strategic move to disrupt healthcare with low-cost, rapid diagnostic tools.

A new 24g wearable device promises clinic-grade laser therapy for just $99. Can its high-power science truly democratize healing, or is it just hype?

Abeona Therapeutics' new treatment center for ZEVASKYN marks a strategic leap in gene therapy access, but what does it mean for patients and the market?

With leadership buying shares and promising trial data for its novel cancer drug, MAIA Biotechnology is sending strong signals to investors. What's next?

As lithium fire risks escalate, a small-cap firm's live EV burn demo in Houston draws industry giants, signaling a pivotal moment for safety tech.

How TerraVest's aggressive acquisition spree is reshaping industrial markets and delivering substantial returns to shareholders. Dive into the strategy.

A once-failed class of weight-loss drugs is back with a new design. Corbus Pharma's early data suggests it may have solved the safety puzzle.

A breakthrough genetic therapy for ALS offers hope, but a split verdict from Canadian health agencies reveals the tough calculus of innovation versus cost.

Beyond its first-ever dividend, Covalon's true story is one of clinical innovation driving record sales, navigating market shifts, and funding global growth.

Promising interim data for a Parkinson's vaccine sends AC Immune's stock soaring, signaling a potential paradigm shift from symptom management to disease modification.

With $70M and a new CEO, Prolynx is leveraging a cancer-tested platform to create monthly obesity shots. Can it disrupt a billion-dollar market?

The EU's landmark decision to ease rules on New Genomic Techniques opens a multi-billion dollar market, and ag-tech pioneer Cibus is ready to cash in.

Apollo Silver plans to revive a massive California silver deposit, aligning with US strategic goals. Can it overcome technical and environmental hurdles?

Sarepta Therapeutics is trading higher interest costs for a longer financial runway. We decode the biotech's complex debt deal and what it signals.

Bristol Myers Squibb's Opdivo gets FDA priority review, backed by landmark data suggesting it could unseat a key competitor as the new gold standard.

By replacing spreadsheets with a cloud platform, New Mexico created a 4.25x funding multiplier, setting a new standard for government efficiency.

One brand’s strategy of selling low-wattage blankets on Amazon reveals a blueprint for success in an era of high energy costs and anxious consumers.

Advantest's T2000 AiR2X isn't just new hardware. It's a calculated move to solve the chip industry's legacy pains and efficiency demands.